BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21280504)

  • 1. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 2. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R; Bergström P; Johansson M; Sandström M
    Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab antiangiogenic therapy for glioblastoma.
    Junck L
    Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fewer dollars, more sense.
    Garfield DH; Hercbergs A
    J Clin Oncol; 2008 Nov; 26(32):5304-5; author reply 5305. PubMed ID: 18854564
    [No Abstract]   [Full Text] [Related]  

  • 7. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 8. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
    Gerstner ER; Emblem KE; Sorensen GA
    Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating biological insights into clinical endpoints in neuro-oncology.
    Bredel M
    Lancet Oncol; 2009 Oct; 10(10):928-9. PubMed ID: 19628430
    [No Abstract]   [Full Text] [Related]  

  • 13. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-angiogenesis treatment for brain tumors: present and future].
    Takano S; Matsumura A
    No Shinkei Geka; 2006 Jul; 34(7):657-78. PubMed ID: 16841703
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Mrugala MM
    Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
    de Boüard S; Guillamo JS
    Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
    Chamberlain MC; Raizer J; Schiff D; Sherman JH
    Neurology; 2010 Jul; 75(3):289-90; author reply 290. PubMed ID: 20644159
    [No Abstract]   [Full Text] [Related]  

  • 20. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.